Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.

Dr Peach has over 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He currently serves on the Board of Directors of Rekover Therapeutics, a privately held biotechnology company in New Zealand. Robert also serves on the Scientific Advisory Board of privately held Eclipse Bioinnovations in San Diego and is a consultant for several other biotechnology companies. Robert is the co-author of 75 scientific publications and book chapters and is an inventor on 17 patents. Dr Peach is a member of the Risk Committee.

Ms Bell is currently Chair of the Risk Committee. She has experience as a Director with a focus in the Medical and Life Sciences sector as well as banking and finance legal experience.

Mr Tong has more than 30 years of experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a variety of roles in the pharmaceutical and biotech industry in NZ (Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). His roles have included; Medical Director, Regional Business Development Director (Asia Pacific), Commercial Strategy Director (International) and SVP Development (USA). He is a Director of Aculeus Therapeutics Pty Ltd, Clear Scientific Pty Ltd and Pacalis Therapeutics Pty Ltd. He was CEO and Director of CTx from 2011 until April 2018. Dr Tong was appointed as a Non-Executive Director on the 4th of May 2018 and Chairman on 25 May 2018. He is a member of the Risk Committee.

Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for over 30 years. After 5 years he returned to Australia taking research leader roles at the University of Sydney and then biotechnology company Ambri. Chris then moved to the Melbourne-based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director. Over this time, he led teams in the discovery of two anti-cancer agents that entered clinical trial (including the approved drug momelotinib). Chris was subsequently recruited to the Walter and Eliza Hall Institute of Medical Research in Melbourne as a Laboratory Head before taking on executive and leadership roles with several privately held biotechnology companies in Melbourne including Certa Therapeutics and MycRx. Dr Burns is the inventor on over 30 patents and a co-author on over 65 scientific publications.

Mr Carter is a biopharmaceutical executive with 25 years' experience across oncology drug development, corporate strategy and business development. Mr Carter spent 11 years with GSK in London, including as a director in the company's global corporate transactions team.

-

-